December 10th & 11th, 2026
15th edition
MARSEILLE, FR
Stand F35/3

2025 Edition

VETBIOLIX

France

VETBIOLIX is a VC-backed, clinical-stage, veterinary biotech company dedicated to the development of First-in-class drug candidates for osteoarthritis (OA), periodontitis (PD) and gut motility disorders. VETBIOLIX is currently leading 2 EU-multicentric, Pilot, randomized, double-blind, dose-ranging, placebo-controlled clinical studies in canine OA (VBX-2000 – A-A3 ag.) and canine PD (VBX-1000 – Cath-K Inh.), and 2 Proof of concept clinical studies in canine / feline GMD (VBX-3000 – 5-HT4 ag.).

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.